Profil
Todd C.
Zankel is the founder of Horizon Pharmaceutical LLC (founded in 2009) and Raptor Pharmaceutical, Inc. (founded in 2006).
At Raptor Pharmaceutical, Inc., he held the title of Chief Scientific Officer.
He was also the founder of Raptor Pharmaceuticals Corp.
(founded in 2006) where he held the title of Chief Scientific Officer in 2009.
Dr. Zankel's former job was as Senior Research Director at BioMarin Pharmaceutical, Inc. from 1997 to 2005.
Dr. Zankel holds a doctorate degree from The Trustees of Columbia University in The City of New York and an undergraduate degree from The Reed Institute.
Anciens postes connus de Todd C. Zankel
| Sociétés | Poste | Fin |
|---|---|---|
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Fondateur | 01/10/2009 |
| BIOMARIN PHARMACEUTICAL INC. | Directeur Technique/Scientifique/R&D | 01/01/2005 |
| RAPTOR PHARMACEUTICAL CORP | Fondateur | - |
| Raptor Pharmaceutical, Inc. | Fondateur | - |
Formation de Todd C. Zankel
| The Reed Institute | Undergraduate Degree |
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
| Raptor Pharmaceutical, Inc. | Health Technology |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Health Technology |